Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

por de Filette, Jeroen, Jansen, Yanina, Schreuer, Max, Everaert, Hendrik, Velkeniers, Brigitte, Neyns, Bart, Bravenboer, Bert
Publicado 2016

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

por Chevolet, Ines, Speeckaert, Reinhart, Schreuer, Max, Neyns, Bart, Krysko, Olga, Bachert, Claus, Van Gele, Mireille, van Geel, Nanja, Brochez, Lieve
Publicado 2015

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

por Schreuer, Max, Meersseman, Geert, Van Den Herrewegen, Sari, Jansen, Yanina, Chevolet, Ines, Bott, Ambre, Wilgenhof, Sofie, Seremet, Teofila, Jacobs, Bart, Buyl, Ronald, Maertens, Geert, Neyns, Bart
Publicado 2016

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients

por Seremet, Teofila, Koch, Alexander, Jansen, Yanina, Schreuer, Max, Wilgenhof, Sofie, Del Marmol, Véronique, Liènard, Danielle, Thielemans, Kris, Schats, Kelly, Kockx, Mark, Van Criekinge, Wim, Coulie, Pierre G., De Meyer, Tim, van Baren, Nicolas, Neyns, Bart
Publicado 2016